Page last updated: 2024-08-23

brimonidine tartrate and Disease Models, Animal

brimonidine tartrate has been researched along with Disease Models, Animal in 54 studies

Research

Studies (54)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (5.56)18.2507
2000's20 (37.04)29.6817
2010's27 (50.00)24.3611
2020's4 (7.41)2.80

Authors

AuthorsStudies
Hu, Y; Liu, J; Lou, X; Zhang, H; Zhao, Y1
Wu, J; Zhang, T; Zhou, X1
Kawamura, A; Kozai, S; Kunikane, E; Kurata, M; Shigemi, W; Shinno, K; Suzuki, G1
Cai, J; Li, L; Mao, Y; Song, Y; Wang, H; Xu, L1
Almazan, A; Andrews-Jones, L; Burke, J; Christie, LA; Engles, M; Ghosn, C; Kulkarni, A; López, FJ; Rajagopalan, L; Tamhane, M1
Jeong, SW; Jo, H; Kim, J; Kim, M; Park, HJ; Woo, YR1
Ciftci, F; Eyuboglu, S; Gumusel, A; Guzel, E; Marangoz, D; Seckin, I; Yalvac, I; Yilmaz, B1
Jiang, X; Li, X; Liu, Y; Lv, H; Wang, Y; Zhang, M1
Gil, D; Hsia, E; Tian, M1
Carr, BJ; Nguyen, CT; Stell, WK1
Diez-Alarcia, R; Horrillo, I; Meana, JJ; Ortega, JE; Urigüen, L1
Chindasub, P; Dai, Y; Duong-Polk, KX; Leung, CK; Lindsey, JD; Weinreb, RN1
Alvarez, T; Aubert, J; de Ménonville, ST; Jomard, A; Piwnica, D; Rosignoli, C; Roye, O; Schuppli Nollet, M1
Johnson, C; Krajnak, K; Miller, GR; Waugh, S1
Alarcón-Martínez, L; Bernal-Garro, JM; García-Ayuso, D; Jiménez-López, M; Nadal-Nicolás, FM; Nieto-López, L; Ortín-Martínez, A; Valiente-Soriano, FJ; Vidal-Sanz, M; Villegas-Pérez, MP; Wheeler, LA1
Agarwal, P; Agarwal, R; Ismail, NM; Kannan Kutty, M; Kapitonova, MY; Razali, N; Salmah Bakar, N; Smirnov, A1
Kitaoka, Y; Kojima, K; Munemasa, Y; Sase, K; Takagi, H1
Jang, I; Jeoung, JW; Kim, H; Kim, KE; Kim, YJ; Moon, H; Park, KH1
Díaz-DelCastillo, M; Galindo-Romero, C; Hallböök, F; Harun-Or-Rashid, M1
Arroba, AI; Beltramo, E; Hernández, C; Lopatina, T; Mazzeo, A; Porta, M; Simó, R; Valverde, AM1
Inada, K; Kawamura, A; Kozai, S; Kurokawa, K; Shinno, K; Tokushige, H1
Agey, P; Dong, CJ; Guo, Y; Hare, WA; Wheeler, L1
Jonas, JB; Ma, K; Pu, M; Xu, L; Zhang, H; Zhang, S1
Avraham-Lubin, BC; Cohen, Y; Dadon-Bar-El, S; Dratviman-Storobinsky, O; Goldenberg-Cohen, N; Hasanreisoglu, M; Weinberger, D1
Gul, M; Imrek, S; Ozdemir, G; Tolun, FI1
Campos, JG; Díaz, F; Moreno, M; Pérez de Vargas, I; Vidal, L; Villena, A1
Dermon, C; Panagis, L; Prokosch, V; Thanos, S; Volk, GF1
Bai, Y; Gil, DW; Kusari, J; Le, YZ; Padillo, E; Song, Z; Wang, J; Zhou, SX; Zhu, M1
Aktaş, S; Cağatay, H; Cumbul, A; Erdenöz, S; Eskicoğlu, E; Oba, E; Uslu, U; Yiğit, U1
Pinar-Sueiro, S; Rivas, MA; Urcola, H; Vecino, E1
Bhagav, P; Chandran, S; Upadhyay, H1
Aburahma, MH; Mahmoud, AA1
Alba-Delgado, C; Berrocoso, E; Borges, G; Horrillo, I; Meana, JJ; Mico, JA; Neto, F; Ortega, JE; Sánchez-Blázquez, P1
Chen, DF; Chen, H; Cho, KS; Guo, W; Luo, G; Pang, IH; Wang, WH; Yang, Q; Yu, D1
Chang, TH; Chen, FA; Chien, ST; Horng, CT; Kao, WT; Tsai, MK; Tsai, ML1
Naskar, R; Quinto, K; Schuettauf, F; Zurakowski, D1
Cai, JJ; Haynes, WG; Lee, HC; Martins, JB; Morgan, DA1
Gendron, ME; Perrault, LP; Thorin, E1
Dong, RG; Flavahan, NA; Flavahan, S; Krajnak, K; Welcome, D1
Aloni, E; Bakalash, S; Ben Simon, GJ; Rosner, M1
Kamata, K; Kobayashi, T; Matsumoto, T1
Alcala, SR; Danylkova, NO; McLoon, LK; Pomeranz, HD1
Hallböök, F; Lafuente, M; Lindqvist, N; Lönngren, U; Mayor, S; Näpänkangas, U; Vidal-Sanz, M1
Aktaş, Z; Akyürek, N; Gürelik, G; Hasanreisoğlu, B; Onol, M1
Avni, I; Barak, A; Ben-Shoshan, J; George, J; Levkovitch-Verbin, H; Luboshits, G; Rosner, M; Schwartz, S; Ziv, H1
Hernández, M; Urcola, JH; Vecino, E1
de Villiers, AS; Jaffer, A; Russell, VA; Sagvolden, T; Searson, A; Taljaard, JJ1
Schwartz, M; Wheeler, LA; Yoles, E1
Edward, DP; Lark, KK; Pasha, AS; Yan, X1
Allie, S; Russell, V; Wiggins, T1
Lagrèze, WA1
Ahmed, FA; Chaudhary, P; Hegazy, K; Sharma, SC1
Grehn, F1
Benozzi, J; Campanelli, JL; Nahum, LP; Rosenstein, RE1

Other Studies

54 other study(ies) available for brimonidine tartrate and Disease Models, Animal

ArticleYear
Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury.
    Journal of nanobiotechnology, 2021, Dec-20, Volume: 19, Issue:1

    Topics: Animals; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen Peroxide; Indoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Nitric Oxide Synthase Type II; Optic Nerve Injuries; Polymers; Reactive Oxygen Species; Retina; Retinal Degeneration; Retinal Ganglion Cells; Transcriptome

2021
Brimonidine enhances inhibitory postsynaptic activity of OFF- and ON-type retinal ganglion cells in a Wistar rat chronic glaucoma model.
    Experimental eye research, 2019, Volume: 189

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Chronic Disease; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glaucoma; Intraocular Pressure; Male; Membrane Potentials; Patch-Clamp Techniques; Presynaptic Terminals; Rats; Rats, Wistar; Retinal Ganglion Cells; Synaptic Transmission

2019
Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
    Current eye research, 2021, Volume: 46, Issue:3

    Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Animals; Aqueous Humor; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Chromatography, High Pressure Liquid; Disease Models, Animal; Drug Compounding; Drug Therapy, Combination; Glaucoma; Male; Ophthalmic Solutions; Rabbits; Sulfonamides; Tandem Mass Spectrometry; Thiazines; Vitreous Body

2021
Neuroprotective Effect of Brimonidine against Facial Nerve Crush Injury in Rats via Suppressing GFAP/PAF Activation and Neuroinflammation.
    ORL; journal for oto-rhino-laryngology and its related specialties, 2021, Volume: 83, Issue:6

    Topics: Animals; Brimonidine Tartrate; Crush Injuries; Disease Models, Animal; Facial Nerve; Facial Nerve Injuries; Mice; Neuroinflammatory Diseases; Neuroprotective Agents; Rats; Rats, Wistar

2021
A nonhuman primate model of blue light-induced progressive outer retina degeneration showing brimonidine drug delivery system-mediated cyto- and neuroprotection.
    Experimental eye research, 2021, Volume: 209

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Choroid; Cytoprotection; Disease Models, Animal; Drug Delivery Systems; Electroretinography; Fluorescein Angiography; Fundus Oculi; Geographic Atrophy; Macaca fascicularis; Neuroprotection; Ophthalmic Solutions; Retinal Photoreceptor Cell Outer Segment; Retinal Pigment Epithelium; Tomography, Optical Coherence; Visual Acuity

2021
Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel.
    Experimental dermatology, 2017, Volume: 26, Issue:11

    Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Animals; Antimicrobial Cationic Peptides; Brimonidine Tartrate; Cathelicidins; Cell Movement; Disease Models, Animal; Enzyme Induction; Enzymes; Female; Gels; Mast Cells; Mice; RNA, Messenger; Rosacea

2017
Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells.
    International ophthalmology, 2018, Volume: 38, Issue:6

    Topics: Animals; Antioxidants; Apoptosis; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Intraocular Pressure; Male; Melatonin; Neuroprotective Agents; Rats; Rats, Wistar; Retinal Ganglion Cells; Tonometry, Ocular

2018
α-adrenergic agonist brimonidine control of experimentally induced myopia in guinea pigs: A pilot study.
    Molecular vision, 2017, Volume: 23

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Disease Models, Animal; Drug Therapy, Combination; Guinea Pigs; Intraocular Pressure; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Pilot Projects; Pirenzepine; Refractive Errors

2017
Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors.
    Experimental dermatology, 2018, Volume: 27, Issue:7

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Calcium; Disease Models, Animal; Erythema; HEK293 Cells; Humans; Male; Mice; Mice, Hairless; Oxymetazoline; Prazosin; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Rosacea; Ultraviolet Rays; Vasoconstriction; Yohimbine

2018
Alpha
    Clinical & experimental optometry, 2019, Volume: 102, Issue:4

    Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Axial Length, Eye; Brimonidine Tartrate; Chickens; Clonidine; Disease Models, Animal; Guanfacine; Intravitreal Injections; Male; Myopia; Sensory Deprivation; Yohimbine

2019
Chronic fluoxetine reverses the effects of chronic corticosterone treatment on α
    Neuropharmacology, 2019, 11-01, Volume: 158

    Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic Neurons; Animals; Antidepressive Agents, Second-Generation; Brimonidine Tartrate; Cell Body; Corticosterone; Dendrites; Disease Models, Animal; Fluoxetine; Guanosine 5'-O-(3-Thiotriphosphate); Hypothalamo-Hypophyseal System; In Vitro Techniques; Isoquinolines; Locus Coeruleus; Male; Microdialysis; Naphthyridines; Norepinephrine; Pituitary-Adrenal System; Prefrontal Cortex; Presynaptic Terminals; Rats; Receptors, Adrenergic, alpha-2; Stress, Psychological; Sulfur Radioisotopes

2019
Brimonidine protects against loss of Thy-1 promoter activation following optic nerve crush.
    BMC ophthalmology, 2013, Jun-27, Volume: 13, Issue:1

    Topics: Adrenergic alpha-2 Receptor Agonists; Analysis of Variance; Animals; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Female; Longitudinal Studies; Male; Mice; Microscopy, Fluorescence; Nerve Crush; Optic Nerve Injuries; Promoter Regions, Genetic; Protective Agents; Quinoxalines; Retinal Ganglion Cells; Thy-1 Antigens

2013
Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine.
    Journal of dermatological science, 2014, Volume: 75, Issue:1

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Biopsy; Brimonidine Tartrate; Disease Models, Animal; Female; Humans; Inflammation; Mice, Inbred BALB C; Quinoxalines; Receptors, Adrenergic, alpha-2; Skin; Tissue Culture Techniques; Vasoconstrictor Agents; Vasodilation

2014
Recovery of vascular function after exposure to a single bout of segmental vibration.
    Journal of toxicology and environmental health. Part A, 2014, Volume: 77, Issue:17

    Topics: Acetylcholine; Animals; Arteries; Brimonidine Tartrate; Disease Models, Animal; Endothelium, Vascular; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Time Factors; Vasoconstriction; Vibration

2014
A novel in vivo model of focal light emitting diode-induced cone-photoreceptor phototoxicity: neuroprotection afforded by brimonidine, BDNF, PEDF or bFGF.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Animals; Brain-Derived Neurotrophic Factor; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Electronics; Eye Proteins; Female; Fibroblast Growth Factor 2; Light; Nerve Growth Factors; Neuroprotective Agents; Quinoxalines; Rats, Sprague-Dawley; Retinal Cone Photoreceptor Cells; Serpins; Time Factors; Tomography, Optical Coherence

2014
Anterior and posterior segment changes in rat eyes with chronic steroid administration and their responsiveness to antiglaucoma drugs.
    European journal of pharmacology, 2015, Feb-15, Volume: 749

    Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Catalase; Dexamethasone; Disease Models, Animal; Female; Glutathione; Intraocular Pressure; Latanoprost; Male; Ocular Hypertension; Oxidative Stress; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Rats, Sprague-Dawley; Retina; Sulfonamides; Superoxide Dismutase; Thiophenes; Timolol

2015
Axonal protection by brimonidine with modulation of p62 expression in TNF-induced optic nerve degeneration.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2015, Volume: 253, Issue:8

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Axons; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Heat-Shock Proteins; Immunoblotting; Immunoenzyme Techniques; Intravitreal Injections; Male; Nerve Degeneration; Optic Nerve Diseases; Rats; Rats, Wistar; Sequestosome-1 Protein; Tumor Necrosis Factor-alpha

2015
Neuroprotective Effects of Human Serum Albumin Nanoparticles Loaded With Brimonidine on Retinal Ganglion Cells in Optic Nerve Crush Model.
    Investigative ophthalmology & visual science, 2015, Volume: 56, Issue:9

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Drug Carriers; Humans; Immunohistochemistry; Intravitreal Injections; Male; Nanoparticles; Nerve Crush; Optic Nerve; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Serum Albumin

2015
Alpha2-Adrenergic-Agonist Brimonidine Stimulates Negative Feedback and Attenuates Injury-Induced Phospho-ERK and Dedifferentiation of Chicken Müller Cells.
    Investigative ophthalmology & visual science, 2015, Volume: 56, Issue:10

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blotting, Western; Brimonidine Tartrate; Cell Dedifferentiation; Cells, Cultured; Chickens; Disease Models, Animal; Ependymoglial Cells; Immunohistochemistry; MAP Kinase Signaling System; Retina; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction

2015
Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy.
    Acta diabetologica, 2016, Volume: 53, Issue:6

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Humans; Male; Microvessels; Neuroprotective Agents; Pericytes; Rats; Receptors, Somatostatin; Retina; Retinal Neurons; Somatostatin; Vascular Endothelial Growth Factor A

2016
The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
    Current eye research, 2017, Volume: 42, Issue:5

    Topics: Administration, Topical; Animals; Antihypertensive Agents; Brimonidine Tartrate; Chromatography, Liquid; Disease Models, Animal; Glaucoma; Male; Melanins; Ophthalmic Solutions; Rabbits; Retina; Tandem Mass Spectrometry; Vitreous Body

2017
Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.
    Investigative ophthalmology & visual science, 2008, Volume: 49, Issue:10

    Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Calcium; Calcium Signaling; Disease Models, Animal; Excitatory Amino Acid Agonists; Glaucoma; Male; N-Methylaspartate; Neuroprotective Agents; Patch-Clamp Techniques; Phosphodiesterase Inhibitors; Quinoxalines; Rabbits; Rats; Rats, Inbred BN; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, N-Methyl-D-Aspartate; Retina; Retinal Ganglion Cells; Rolipram

2008
Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model.
    American journal of ophthalmology, 2009, Volume: 147, Issue:2

    Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Disease Models, Animal; Injections, Intraperitoneal; Nerve Crush; Neuroprotective Agents; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells

2009
Possible neuroprotective effect of brimonidine in a mouse model of ischaemic optic neuropathy.
    Clinical & experimental ophthalmology, 2009, Volume: 37, Issue:7

    Topics: Animals; Brimonidine Tartrate; Disease Models, Animal; Eye Proteins; Fluorescent Antibody Technique, Indirect; Gene Expression; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Heme Oxygenase-1; Hypoxia-Inducible Factor 1, alpha Subunit; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factors; Neuroprotective Agents; Nitric Oxide Synthase Type III; Optic Neuropathy, Ischemic; Oxidative Stress; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, TIE-2; Retinal Ganglion Cells; Retinal Neovascularization; Serpins; Superoxide Dismutase; Superoxide Dismutase-1; Vascular Endothelial Growth Factor A

2009
Retinal oxidative stress induced by intraocular hypertension in rats may be ameliorated by brimonidine treatment and N-acetyl cysteine supplementation.
    Journal of glaucoma, 2009, Volume: 18, Issue:9

    Topics: Acetylcysteine; Animals; Brimonidine Tartrate; Catalase; Disease Models, Animal; Drug Therapy, Combination; Glutathione Peroxidase; Hyaluronic Acid; Intraocular Pressure; Male; Malondialdehyde; Nitric Oxide; Ocular Hypertension; Oxidative Stress; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Diseases; Tonometry, Ocular

2009
Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine.
    Brain research bulletin, 2010, Apr-29, Volume: 82, Issue:1-2

    Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Glial Fibrillary Acidic Protein; Gliosis; Intraocular Pressure; Latanoprost; Male; Neuroglia; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Retina; Timolol; Tonometry, Ocular

2010
Alpha2-adrenergic receptors and their core involvement in the process of axonal growth in retinal explants.
    Investigative ophthalmology & visual science, 2010, Volume: 51, Issue:12

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Autoradiography; Axons; Brimonidine Tartrate; Clonidine; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Fluorescent Antibody Technique, Indirect; Glaucoma; Glial Fibrillary Acidic Protein; Optic Nerve Injuries; Organ Culture Techniques; Platelet Activating Factor; Protein Disulfide-Isomerases; Proteomics; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Laminin; Retina; Retinal Degeneration; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2010
Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats.
    Investigative ophthalmology & visual science, 2011, Jul-20, Volume: 52, Issue:8

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Choroidal Neovascularization; Disease Models, Animal; Dose-Response Relationship, Drug; Fibroblast Growth Factor 2; Fluorescein Angiography; Humans; Immunoblotting; Infant, Newborn; Intravitreal Injections; Laser Coagulation; Male; Mice; Mice, Inbred C57BL; Oxygen; Quinoxalines; Rabbits; Rats; Rats, Inbred BN; Retinal Neovascularization; Retinopathy of Prematurity; Time Factors

2011
An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury.
    Molecular vision, 2011, Apr-26, Volume: 17

    Topics: Animals; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Hyperbaric Oxygenation; Immunohistochemistry; Injections, Intravenous; Memantine; Neuroprotective Agents; Ophthalmic Solutions; Quinoxalines; Rats; Rats, Wistar; Reperfusion Injury; Retina; Retinal Ganglion Cells

2011
Prevention of retinal ganglion cell swelling by systemic brimonidine in a rat experimental glaucoma model.
    Clinical & experimental ophthalmology, 2011, Volume: 39, Issue:8

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glaucoma, Open-Angle; Injections, Intraperitoneal; Intraocular Pressure; Papilledema; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Treatment Outcome

2011
Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.
    AAPS PharmSciTech, 2011, Volume: 12, Issue:4

    Topics: Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Chemistry, Pharmaceutical; Delayed-Action Preparations; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Glaucoma; Hydrogen-Ion Concentration; Intraocular Pressure; Kinetics; Nanoparticles; Nanotechnology; Quinoxalines; Rabbits; Solubility; Technology, Pharmaceutical

2011
Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation.
    AAPS PharmSciTech, 2011, Volume: 12, Issue:4

    Topics: Absorbable Implants; Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Alginates; Animals; Brimonidine Tartrate; Calorimetry, Differential Scanning; Cellulose; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Compounding; Glaucoma; Glucuronic Acid; Hexuronic Acids; Hydrophobic and Hydrophilic Interactions; Hypromellose Derivatives; Intraocular Pressure; Kinetics; Methylcellulose; Ophthalmic Solutions; Polymers; Polymethacrylic Acids; Polyvinyls; Povidone; Quinoxalines; Rabbits; Solubility; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; X-Ray Diffraction

2011
The function of alpha-2-adrenoceptors in the rat locus coeruleus is preserved in the chronic constriction injury model of neuropathic pain.
    Psychopharmacology, 2012, Volume: 221, Issue:1

    Topics: Action Potentials; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Brimonidine Tartrate; Clonidine; Desipramine; Disease Models, Animal; Idazoxan; Locus Coeruleus; Male; MAP Kinase Signaling System; Medulla Oblongata; Neuralgia; Norepinephrine; Prefrontal Cortex; Quinoxalines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Signal Transduction; Spinal Cord

2012
Microbead-induced ocular hypertensive mouse model for screening and testing of aqueous production suppressants for glaucoma.
    Investigative ophthalmology & visual science, 2012, Jun-20, Volume: 53, Issue:7

    Topics: Animals; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Feasibility Studies; Intraocular Pressure; Latanoprost; Mice; Mice, Inbred C57BL; Microspheres; Muscarinic Agonists; Ocular Hypertension; Optic Nerve; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Retinal Ganglion Cells; Sulfonamides; Thiazines; Timolol; Tomography, Optical Coherence

2012
The activity of lowering intraocular pressure of cassiae seed extract in a DBA/2J mouse glaucoma model.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2013, Volume: 29, Issue:1

    Topics: Acetazolamide; Animals; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Cassia; Chromatography, High Pressure Liquid; Disease Models, Animal; Glaucoma; Glycosides; Intraocular Pressure; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred DBA; Plant Extracts; Polyphenols; Quinoxalines; Seeds

2013
Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model.
    Vision research, 2002, Volume: 42, Issue:20

    Topics: Aging; Analysis of Variance; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Glaucoma; Memantine; Mice; Mice, Inbred DBA; Quinoxalines; Retinal Ganglion Cells; Timolol

2002
Alpha 2-Adrenergic stimulation is protective against ischemia-reperfusion-induced ventricular arrhythmias in vivo.
    American journal of physiology. Heart and circulatory physiology, 2002, Volume: 283, Issue:6

    Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Brimonidine Tartrate; Disease Models, Animal; Electrocardiography; Female; Heart Rate; Kidney; Male; Myocardial Ischemia; Myocardial Reperfusion; Quinoxalines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sympathetic Nervous System; Tachycardia, Ventricular; Ventricular Fibrillation

2002
Loss of endothelial KATP channel-dependent, NO-mediated dilation of endocardial resistance coronary arteries in pigs with left ventricular hypertrophy.
    British journal of pharmacology, 2004, Volume: 143, Issue:2

    Topics: Adenosine Triphosphate; Animals; Bradykinin; Brimonidine Tartrate; Canada; Charybdotoxin; Coronary Vessels; Disease Models, Animal; Drug Therapy, Combination; Endocardium; Endothelium, Vascular; Glyburide; Guanylate Cyclase; Hemodynamics; Hypertrophy, Left Ventricular; Indomethacin; Male; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Nitroprusside; Oxadiazoles; Potassium Channels; Quinoxalines; Swine; Vascular Resistance; Vasodilation

2004
Acute vibration increases alpha2C-adrenergic smooth muscle constriction and alters thermosensitivity of cutaneous arteries.
    Journal of applied physiology (Bethesda, Md. : 1985), 2006, Volume: 100, Issue:4

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Arteries; Body Temperature Regulation; Brimonidine Tartrate; Cold Temperature; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Muscle, Smooth, Vascular; Neuromuscular Diseases; Quinolizines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Skin; Tail; Vasoconstriction; Vibration

2006
A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy.
    American journal of ophthalmology, 2006, Volume: 141, Issue:6

    Topics: Acute Disease; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Dizocilpine Maleate; Glatiramer Acetate; Immunization; Injections; Intraocular Pressure; Male; Neuroprotective Agents; Ocular Hypertension; Optic Nerve Diseases; Peptides; Quinoxalines; Rats; Rats, Inbred Lew; Retinal Ganglion Cells; Vaccination

2006
Mechanisms underlying lysophosphatidylcholine-induced potentiation of vascular contractions in the Otsuka Long-Evans Tokushima Fatty (OLETF) rat aorta.
    British journal of pharmacology, 2006, Volume: 149, Issue:7

    Topics: Animals; Aorta, Thoracic; Brimonidine Tartrate; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Lysophosphatidylcholines; Male; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Potassium; Protein Kinase Inhibitors; Protein Tyrosine Phosphatases; Quinoxalines; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Receptors, G-Protein-Coupled; RNA, Messenger; Up-Regulation; Vanadates; Vasoconstriction; Vasoconstrictor Agents

2006
Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy.
    Experimental eye research, 2007, Volume: 84, Issue:2

    Topics: Adrenergic alpha-Agonists; Animals; Axons; Benzoxazines; Brimonidine Tartrate; Cell Survival; Coloring Agents; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Neuroprotective Agents; Ophthalmic Solutions; Optic Neuropathy, Ischemic; Oxazines; Quinoxalines; Rats; Rats, Long-Evans; Retinal Ganglion Cells

2007
The growth factor response in ischemic rat retina and superior colliculus after brimonidine pre-treatment.
    Brain research bulletin, 2006, Dec-11, Volume: 71, Issue:1-3

    Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Axons; Brain Ischemia; Brimonidine Tartrate; Cytoprotection; Disease Models, Animal; Gene Expression Regulation; Intercellular Signaling Peptides and Proteins; Male; Nerve Degeneration; Neuroprotective Agents; Optic Nerve; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Growth Factor; Retinal Ganglion Cells; RNA, Messenger; Superior Colliculi; Up-Regulation

2006
Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model.
    Clinical & experimental ophthalmology, 2007, Volume: 35, Issue:6

    Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Endothelin-1; Infusion Pumps, Implantable; Neuroprotective Agents; Optic Neuropathy, Ischemic; Quinoxalines; Rabbits; Retina; Retinal Ganglion Cells

2007
Drug modification of angiogenesis in a rat cornea model.
    Investigative ophthalmology & visual science, 2008, Volume: 49, Issue:1

    Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Corneal Neovascularization; Corneal Stroma; Disease Models, Animal; Drug Implants; Fibroblast Growth Factor 2; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Sulfonamides; Thiophenes; Timolol

2008
Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments.
    Experimental eye research, 2008, Volume: 86, Issue:5

    Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Intraocular Pressure; Latanoprost; Neuroprotective Agents; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells

2008
Alpha 2-adrenoceptor mediated inhibition of [3H]dopamine release from nucleus accumbens slices and monoamine levels in a rat model for attention-deficit hyperactivity disorder.
    Neurochemical research, 1995, Volume: 20, Issue:4

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antihypertensive Agents; Attention Deficit Disorder with Hyperactivity; Biogenic Monoamines; Brimonidine Tartrate; Disease Models, Animal; Dopamine; Hypertension; In Vitro Techniques; Male; Neurons; Norepinephrine; Nucleus Accumbens; Quinoxalines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Adrenergic, alpha-2; Tritium

1995
Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.
    Investigative ophthalmology & visual science, 1999, Volume: 40, Issue:1

    Topics: Action Potentials; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Axons; Brimonidine Tartrate; Cell Count; Cell Survival; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Nerve Degeneration; Neuroprotective Agents; Optic Nerve; Optic Nerve Diseases; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Retinal Ganglion Cells; Timolol; Yohimbine

1999
The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts.
    Journal of glaucoma, 1999, Volume: 8, Issue:1

    Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Division; Conjunctiva; Disease Models, Animal; Fibroblasts; Glaucoma; Intraocular Pressure; Latanoprost; Microfilament Proteins; Ophthalmic Solutions; Proliferating Cell Nuclear Antigen; Prostaglandins F, Synthetic; Quinoxalines; Rabbits

1999
Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat.
    Behavioural brain research, 2000, Dec-20, Volume: 117, Issue:1-2

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Brimonidine Tartrate; Disease Models, Animal; Dopamine; Down-Regulation; Hypertension; Idazoxan; In Vitro Techniques; Male; Models, Neurological; Norepinephrine; Prefrontal Cortex; Quinoxalines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Long-Evans; Receptors, Adrenergic, alpha-2

2000
[Neuroprotection. Bases and possibilities of a future clinical use].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2001, Volume: 98, Issue:3

    Topics: Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Eye Diseases; Forecasting; Glaucoma; Humans; Memantine; Neuroprotective Agents; Optic Neuritis; Quinoxalines; Retinal Diseases; Visual Fields

2001
Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure.
    Brain research, 2001, Sep-21, Volume: 913, Issue:2

    Topics: Adrenergic alpha-Antagonists; Age Factors; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Disease Models, Animal; Female; Glaucoma; Intraocular Pressure; Nerve Degeneration; Neuroprotective Agents; Quinoxalines; Rats; Rats, Wistar; Retinal Ganglion Cells; Time Factors

2001
[Prospects for neuroprotective glaucoma therapy].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2001, Volume: 98, Issue:10

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Betaxolol; Brain-Derived Neurotrophic Factor; Brimonidine Tartrate; Calcium Channel Blockers; Disease Models, Animal; Dopamine Agents; Glaucoma; Glaucoma, Open-Angle; Haplorhini; Humans; Memantine; Neuroprotective Agents; Nimodipine; Nitric Oxide Synthase; Quinoxalines; Receptors, N-Methyl-D-Aspartate

2001
Effect of hyaluronic acid on intraocular pressure in rats.
    Investigative ophthalmology & visual science, 2002, Volume: 43, Issue:7

    Topics: Animals; Anterior Chamber; Antihypertensive Agents; Brimonidine Tartrate; Disease Models, Animal; Hyaluronic Acid; Injections; Intraocular Pressure; Latanoprost; Male; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Timolol; Tonometry, Ocular

2002